GT-19630 inhibits proliferation, promotes apoptosis and blocks migration of breast cancer cells
March 1, 2024
At this week’s EACR-AACR-ICAR meeting in Dublin, Suzhou Kintor Pharmaceuticals Inc. presented preclinical data for the novel MYC- and GSPT1-targeting molecular glue candidate, GT-19630, being developed for the treatment of breast cancer.